Today on DrugResearcher.com
 
Analysts fear severe delay for Arpida antibiotic

Big pharma learning drug safety lessons

Nicholas Piramal to spin off R&D unit

MicroCal pushes ITC towards secondary screening applications

R&D news in brief

 
   
Related Industry News
 
Sanofi-Aventis faces a second patent lawsuit for SoloStar

Synthetic MAb purification tech edges closer to market

First US cell-based flu vaccine plant underway

Indian drug manufacturers must clean up their act

 
 

Drug discovery

Breaking News on Drug Discovery
Daily  Tuesday 28 August 2007 Forward to a colleague

Product Overview

PharmatestPre-Clinical Contract Research - Free Download

Pharmatest offers unique preclinical in vitro and in vivo drug efficacy testing services to pharmaceutical companies developing new drugs against osteoporosis, cancer or osteoarthritis. Our services can also be used for testing existing compounds for possible adverse effects on bone or secondary indication for bone-related diseases, as well as development of functional foods for bone health... Click Here


Access Full Stories



Analysts fear severe delay for Arpida antibiotic
New data have raised 'serious questions' about whether Arpida's new antibiotic will be approved by industry regulators, according to one analyst's report... Read


Big pharma learning drug safety lessons
Big pharma is learning from past failures to improve its ability to predict drug toxicity earlier in the development process... Read


Nicholas Piramal to spin off R&D unit
Nicholas Piramal is the latest Indian pharma firm planning to spin off its new chemical entity (NCE) research unit as its pipeline is maturing... Read


MicroCal pushes ITC towards secondary screening applications
The launch of the world's fastest isothermal titration calorimeter (ITC) could herald a new dawn for a technique traditionally hampered by throughput limitations and the need for large amounts of sample... Read


R&D news in brief
In a round up of the latest news in pharma research, Pfizer and Bristol-Myers Squibb have big plans for DGAT-1 in obesity and diabetes, GlaxoSmithKline is extra keen on Exelixis' anticancer drug, Takeda is talking... Read


All News Headlines for:
August | July | June

DrugResearcherProduct Overview

A revolution in Sales Lead Generation! - Free Download

Promote your products and technology towards our readers, and we'll build a detailed profile of each person who reads your presentation document... Download our FREE Smart Lead Generation brochure now!... Click Here
Related Industry News



Sanofi-Aventis faces a second patent lawsuit for SoloStar
Sanofi-Aventis has been hit with its second patent lawsuit in two months over its recently released SoloStar insulin pen... Read


Synthetic MAb purification tech edges closer to market
The UK arm of biopharma company ProMetic has hit a milestone with its breakthrough synthetic molecule solution for protein purification... Read


First US cell-based flu vaccine plant underway
Novartis last week began construction of a major new flu vaccine manufacturing facility in North Carolina, the very first cell culture-derived flu vaccine plant in the United States... Read


Indian drug manufacturers must clean up their act
New research has branded pharmaceutical manufacturers in India as being responsible for the release of substantial and worrying amounts of active pharmaceutical ingredients (APIs) into the environment... Read

Weekly comment

UK tightens Phase I guidelines

The Association of the British Pharmaceutical Industry (ABPI) has now published revised guidelines for Phase I trials in the UK. Read



KSV InstrumentsTechnical / White Paper

Surface Characterization by Contact Angle

From paints and coatings to biotechnology to nanotechnology, contact angle provides a quick, easy and sensitive measure of surface quality and cleanliness in research, QC and process control... Click Here

Previous Headlines



Novartis turns its back on India
Novartis is to pull millions of planned investment dollars out of India in reaction to intellectual property (IP) fears. The decision may leave China as the cat that got the cream... Read


Amgen expounds IL-17 potential as arthritis target
Amgen is rushing to discover how interleukin-17 causes inflammation and bone destruction in rheumatoid arthritis, as it could provide a valuable new therapeutic target... Read


Pfizer expands biologics R&D
Pfizer is breaking ground on a $50m expansion of its biologics pilot plant in Chesterfield, at a time when the drug giant is cutting back in other business areas... Read


Drugs moving into the clinic: 25
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators... Read


Merck KGaA disappointed by Parkinson's drug results
Newron Pharmaceuticals and its partner Merck KGaA suffered a disappointment yesterday, when their investigational Parkinson's disease drug failed a pivotal clinical trial... Read

Product Innovation Alerts - Free of Charge
Indicate your research interests and receive alerts on relevant products and market innovations
Analysis and instrumentation
Assays and screening
Cell culture & Equipment
Chromatography
Compounds and consumables
Contract services (outsourcing)
Drug discovery
Genomics / Proteomics
Informatics & IT
Lab equipment & consumables
Liquid handling and automation
Liquid handling and sample preparation
Production technologies
Separation and purification




Free Newsletters for Pharmaceuticals
Access now !Choose from over 20 industry e-newsletters
Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here

Forward to a colleague

To continue to receive this newsletter in your inbox, please add
newsletter@DrugResearcher.com to your address book

Update preferences | Change your email address | Unsubscribe

Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback

© 2007 - Decision News Media S.A.S - All Rights Reserved
Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France
http://www.decisionnewsmedia.com